Gaudreau PO, Negrao MV, Mitchell KG, Reuben A, Corsini EM, Li J, Karpinets TV, Wang Q, Diao L, Wang J, Federico L, Parra-Cuentas ER, Khairullah R, Behrens C, Correa AM, Gomez D, Little L, Gumbs C, Kadara HN, Fujimoto J, McGrail DJ, Vaporciyan AA, Swisher SG , Walsh G, Antonoff MB, Weissferdt A, Tran H, Roarty E, Haymaker C, Bernatchez C, Zhang J, Futreal PA, Wistuba II, Cascone T, Heymach JV, Sepesi B, Zhang J, Gibbons DL
10.1186/s13048-024-01489-y 96 MontanoL.BaldiniG
Disclosures: Felice Cinque: Nothing to Disclose, Andrea Dalbeni: Nothing to Disclose, Annalisa Cespiati: Nothing to Disclose, Floriana Santomenna: Nothing to Disclose, Jaqueline Curr: Nothing to Disclose, Daniel Smith: Nothing to Disclose, Erika Fatta: Nothing to Disclose, Cristina Bertelli: Nothing to Disclose, Giovanna Oberti: Nothing to Disclose, Giuseppina Pisano: Nothing to Disclose, Gabriele Maffi: Nothing to Disclose, Edoardo Pulixi: Nothing to Disclose, Alessandro Mantovani: Nothing to Disclose, Mirko Zoncap: Nothing to Disclose, David Sacerdoti: Nothing to Disclose, Anna Fracanzani: Nothing to Disclose, Rosa Lombardi: Nothing to Disclose 1130 ASSOCIATION OF BMI TRAJECTORY WITH MORTALITY AMONG NON-ALCOHOLIC FATTY LIVER DISEASE INDIVIDUALS: A PROSPECTIVE COHORT STUDY Junping Shi 1 Pengwei Zhang 1 Xianhui Dong 1 Yixuan Zhu 2 Run zhou 1 Fajuan Rui 2 Jie Li 2 Li Li 1 , 1 The Affiliated Hospital of Hangzhou Normal University, 2 Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School Background: Weight is a dynamically changing physiological indicator, the relationship between historical weight trends and mortality in patients with Non-alcoholic fatty liver disease (NAFLD) remains unclear
Le glutathion oral pose un dfi pharmacologique majeur : ce tripeptide est naturellement dgrad par la gamma-glutamyltransfrase intestinale avant d'atteindre la circulation systmique, ce qui limite fortement sa biodisponibilit sous forme classique (poudre libre, glule non protge)
